Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Equity Average (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Equity Average for 12 consecutive years, with $570.5 million as the latest value for Q1 2026.

  • For Q1 2026, Equity Average fell 33.94% year-over-year to $570.5 million; the TTM value through Mar 2026 reached $570.5 million, down 33.94%, while the annual FY2025 figure was $759.7 million, 23.65% up from the prior year.
  • Equity Average hit $570.5 million in Q1 2026 for Viking Therapeutics, down from $676.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $927.4 million in Q2 2024 and bottomed at $139.7 million in Q1 2023.
  • Average Equity Average over 5 years is $522.0 million, with a median of $570.5 million recorded in 2026.
  • Year-over-year, Equity Average surged 358.97% in 2024 and then crashed 33.94% in 2026.
  • Viking Therapeutics' Equity Average stood at $148.3 million in 2022, then surged by 141.62% to $358.3 million in 2023, then soared by 150.01% to $895.9 million in 2024, then decreased by 24.54% to $676.0 million in 2025, then fell by 15.61% to $570.5 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $570.5 million, $676.0 million, and $754.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.